Genetic and epigenetic regulations of prostate cancer by Genistein

Drug News and Perspectives

Volumn 22, Issue 5, 2009, Pages 247-254

  Molinié, Benoit ^a   Georgel, Philippe ^a  

^a MARSHALL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; ISOFLAVONOID;

ANTINEOPLASTIC ACTIVITY; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC REGULATION; HUMAN; NONHUMAN; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 70350070121     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.5.1378633     Document Type: Review

References (104)

1. Barnes, S. and Peterson, T.G. Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 1995, 208(1): 103-108
2. Wel, H., Bowen, R., Cai, Q., Barnes, S. and Wang, Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 1995, 208(1): 124-130
3. Shimizu, H., Ross, R.K., Bernstein, L., Yatani, R., Henderson, B.E. and Mack, T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991, 63(6): 963-966
4. Messina, M. and Barnes, S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991, 83(8): 541-546
5. Messina, M. and Messina, V. Increasing use of soyfoods and their potential role in cancer prevention. J Am Diet Assoc 1991, 91(7): 836-840
6. Perabo, F.G., Von Low, E.C., Ellinger, J., von Rucker, A., Muller, S.C. and Bastian, P.J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2008, 11(1): 6-12. (Pubitemid 351250324)
7. Lee, M.M., Gomez, S.L., Chang, J.S., Wey, M., Wang, R.T. and Hsing, A.W. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003, 12(7): 665-668 (Pubitemid 36899850)
8. Kurahashi, N., Iwasaki, M., Sasazuki, S., Otani, T., Inoue, M. and Tsugane, S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007, 16(3): 538-545 (Pubitemid 46548658)
9. Greenlee, R.T., Murray, T., Bolden, S. and Wingo, P.A. Cancer statistics, 2000. CA Cancer J Clin 2000, 50(1): 7-33.
10. Lee, S.A., Wen, W., Xiang, Y.B. et al. Assessment of dietary isoflavone intake among middle-aged Chinese men. J Nutr 2007, 137(4): 1011-1016 (Pubitemid 46596902)
11. Steiner, C., Arnould, S., Scalbert, A. and Manach, C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008, 99 E Suppl 1: ES78-108.
12. Banerjee, S., Li, Y., Wang, Z. and Sarkar, F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008, 269(2): 226-242
13. Helferich, W.G., Andrade, J.E. and Hoagland, M.S. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008, 16(5): 219-226
14. Bektic, J., Guggenberger, R., Eder, I.E. et al. Molecular effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer 2005, 4(2): 124-129 (Pubitemid 41474608)
15. Lamartiniere, C.A., Moore, J.B., Brown, N.M., Thompson, R., Hardin, M.J. and Barnes, S. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995, 16(11): 2833-2840
16. Wang, J., Eltoum, I.E. and Lamartiniere, C.A. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 2002, 186(1): 11-18 (Pubitemid 35245321)
17. Lamartiniere, C.A., Cotroneo, M.S., Fritz, W.A., Wang, J., Mentor-Marcel, R. and Elgavish, A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002, 132(3): 552S-8S. (Pubitemid 34208769)
18. Peterson, G. and Barnes, S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991, 179(1): 661-667
19. Peterson, G. and Barnes, S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993, 22(4): 335-345 (Pubitemid 23176275)
20. Zava, D.T. and Duwe, G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997, 27(1): 31-40. (Pubitemid 26424313)
21. Okura, A., Arakawa, H., Oka, H., Yoshinari, T. and Monden, Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 1988, 157(1): 183-189
22. Markovits, J., Linassier, C., Fosse, P. et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989, 49(18): 5111-5117 (Pubitemid 19239354)
23. Matsukawa, Y., Marui, N., Sakai, T. et al. Genistein arrests cell cycle progression at G2- M. Cancer Res 1993, 53(6): 1328-1331 (Pubitemid 23097111)
24. Peterson, G. Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 1995, 125(3 Suppl): 784S-9S.
25. Li, M., Zhang, Z., Hill, D.L., Chen, X., Wang, H. and Zhang, R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005, 65(18): 8200-8208 (Pubitemid 41330583)
26. Li, Y. and Sarkar, F.H. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002, 132(12): 3623-3631 (Pubitemid 35435038)
27. Setchell, K.D., Borriello, S.P., Hulme, P., Kirk, D.N. and Axelson, M. Nonsteroidal estrogens of dietary origin: possible roles in hormone- dependent disease. Am J Clin Nutr 1984, 40(3): 569-578 (Pubitemid 14035518)
28. Adlercreutz, H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 1990, 201: 3-23. (Pubitemid 20271058)
29. Murrill, W.B., Brown, N.M., Zhang, J.X., Manzolillo, P.A., Barnes, S. and Lamartiniere, C.A. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 1996, 17(7): 1451-1457 (Pubitemid 26242650)
30. Matsumura, K., Tanaka, T., Kawashima, H. and Nakatani, T. Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells. Anticancer Res 2008, 28(2A): 709-714 (Pubitemid 351578912)
31. Smith, S., Sepkovic, D., Bradlow, H.L. and Auborn, K.J. 3,3′-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr 2008, 138(12): 2379-2385
32. Lintula, S., Stenman, J., Bjartell, A., Nordling, S. and Stenman, U.H. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005, 63(4): 324-329 (Pubitemid 40664343)
33. Cicek, M.S., Liu, X., Casey, G. and Witte, J.S. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005, 14(9): 2173-2177
34. Onozawa, M., Fukuda, K., Ohtani, M., Akaza, H., Sugimura, T. and Wakabayashi, K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 1998, 28(6): 360-363 (Pubitemid 128522964)
35. Davis, J.N., Muqim, N., Bhuiyan, M., Kucuk, O., Pienta, K.J. and Sarkar, F.H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 2000, 16(6): 1091-1097
36. Jia, L., Kim, J., Shen, H., Clark, P.E., Tilley, W.D. and Coetzee, G.A. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res 2003, 1(5): 385-392 (Pubitemid 36437924)
37. Jia, L., Shen, H.C., Wantroba, M. et al. Locus- wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006, 26(19): 7331-7341 (Pubitemid 44477706)
38. Akiyama, T., Ishida, J., Nakagawa, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262(12): 5592-5595
39. Rokhlin, O.W. and Cohen, M.B. Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors. Cancer Lett 1995, 98(1): 103-110
40. Wang, J., Eltoum, I.E. and Lamartiniere, C.A. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol 2004, 219(1-2): 171-180 (Pubitemid 38638530)
41. Skogseth, H., Holt, R.U., Larsson, E. and Halgunset, J. Tyrosine kinase inhibitors alter adheslvity of prostatic cancer cells to extracellular matrix components. APMIS 2006, 114(3): 225-233
42. Skogseth, H., Larsson, E. and Halgunset, J. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase. APMIS 2006, 114(1): 61-66 (Pubitemid 43356836)
43. Kiguchi, K., Constantinou, A.I. and Huberman, E. Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. Cancer Commun 1990, 2(8): 271-277 (Pubitemid 20354889)
44. McCabe, M.J., Jr. and Orrenius, S. Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem Biophys Res Commun 1993, 194(2): 944-950 (Pubitemid 23245226)
45. Bergamaschi, C., Rosti, V., Danova, M., Ponchio, L., Lucotti, C. and Cazzola, M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia 1993, 7(12): 2012-2018 (Pubitemid 24003221)
46. Burden, D.A., Goldsmith, L.J. and Sullivan, D.M. Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. Biochem J 1993, 293(Pt 1): 297-304.
47. Suzuki, K., Koike, H., Matsui, H. et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 2002, 99(6): 846-852 (Pubitemid 34575703)
48. Davis, J.N., Kucuk, O. and Sarkar, F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999, 35(2): 167-174 (Pubitemid 30115128)
49. Li, Y. and Sarkar, F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002, 8(7): 2369-2377 (Pubitemid 34753612)
50. Zhou, J.R., Gugger, E.T., Tanaka, T., Guo, Y., Blackburn, G.L. and Clinton, S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesls in mice. J Nutr 1999, 129(9): 1628-1635 (Pubitemid 29406613)
51. Po, L.S., Wang, T.T., Chen, Z.Y. and Leung, L.K. Genistein-induced apoptosis in MCF-7 cells involves changes in Bak and Bcl-x without evidence of anti-oestrogenic effects. Br J Nutr 2002, 88(5): 463-469
52. Li, Y., Upadhyay, S., Bhuiyan, M. and Sarkar, F.H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999, 18(20): 3166-3172 (Pubitemid 29261238)
53. Shen, J.C., Klein, R.D., Wei, Q. et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000, 29(2): 92-102.
54. Kazi, A., Daniel, K.G., Smith, D.M., Kumar, N.B. and Dou, Q.P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003, 66(6): 965-976 (Pubitemid 37083593)
55. Li, X., Marani, M., Mannucci, R. et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001, 61(4): 1699-1706
56. Bemis, D.L., Capodice, J.L., Desai, M., Buttyan, R. and Katz, A.E. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004, 10(15): 5282-5292 (Pubitemid 39099803)
57. Cao, F., Jin, T.Y. and Zhou, Y.F. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci 2006, 19(1): 35-41.
58. Ouchi, H., Ishiguro, H., Ikeda, N., Hori, M., Kubota, Y. and Uemura, H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005, 12(1): 73-80. (Pubitemid 40333005)
59. Zetter, B.R. Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49: 407-424
60. Singh-Gupta, V., Zhang, H., Banerjee, S. et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 2009, 124(7): 1675-1684
61. Guo, Y., Wang, S., Hoot, D.R. and Clinton, S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007, 18(6): 408-417 (Pubitemid 46727041)
62. Zhang, L.L., Li, L., Wu, D.P. et al. A novel anticancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin 2008, 29(9): 1060-1068
63. Salnikow, K., Costa, M., Figg, W.D. and Blagosklonny, M.V. Hyperinducibility of hypoxia-responsive genes without p53/p21-depend- ent checkpoint in aggressive prostate cancer. Cancer Res 2000, 60(20): 5630-5634 (Pubitemid 30808293)
64. Meng, A.X., Jalali, F., Cuddihy, A. et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005, 76(2): 168-176 (Pubitemid 41725444)
65. Frey, R.S., Li, J. and Singletary, K.W. Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21(waf/cip1), p27(kip1), and Cdc25C expression. Biochem Pharmacol 2001, 61(8): 979-989
66. Davis, J.N., Singh, B., Bhuiyan, M. and Sarkar, RH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998, 32(3): 123-131 (Pubitemid 29081398)
67. Wang, S., DeGroff, V.L. and Clinton, S.K. Tomato and soy polyphenols reduce insulin- like growth factor-1-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003, 133(7): 2367-2376 (Pubitemid 36841567)
68. Majid, S., Kikuno, N., Nelles, J. et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008, 68(8): 2736-2744 (Pubitemid 351556271)
69. Kumi-Diaka, J.K., Hassanhi, M., Merchant, K. and Horman, V. Influence of genistein isoflavone on matrix metalloproteinase-2 expression in prostate cancer cells. J Med Food 2006, 9(4): 491-497 (Pubitemid 46095357)
70. Weber, M. and Schubeler, D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol 2007, 19(3): 273-280 (Pubitemid 46899512)
71. Suzuki, M.M. and Bird, A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 9(6): 465-476 (Pubitemid 351693975)
72. Jenuwein, T. and Allis, C.D. Translating the histone code. Science 2001, 293(5532): 1074-1080
73. Meehan, R.R., Lewis, J.D. and Bird, A.P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 1992, 20(19): 5085-5092
74. Georgel, P.T., Horowitz-Scherer, R.A., Adkins, N., Woodcock, C.L., Wade, P.A. and Hansen, J.C. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J Biol Chem 2003, 278(34): 32181-32188 (Pubitemid 37048409)
75. Nikitina, T., Shi, X., Ghosh, R.P., Horowitz- Scherer, R.A., Hansen, J.C. and Woodcock, C.L. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol Cell Biol 2007, 27(3): 864-877 (Pubitemid 46174552)
76. Taverna, S.D., Li, H., Ruthenburg, A.J., Allis, C.D. and Patel, D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007, 14(11): 1025-1040 (Pubitemid 350060344)
77. Li, H., Fischle, W., Wang, W. et al. Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. Mol Cell 2007, 28(4): 677-691 (Pubitemid 350137797)
78. Abreu, P.A., Dellamora-Ortiz, G., Leao- Ferreira, L.R. et al. DNA methylation: a promising target for the twenty-first century. Expert Opin Ther Targets 2008, 12(8): 1035-1047
79. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21(35): 5400-5413 (Pubitemid 34983477)
80. Fang, M., Chen, D. and Yang, C.S. Dietary polyphenols may affect DNA methylation. J Nutr 2007, 137(1 Suppl): 223S-8S. (Pubitemid 46052885)
81. Schulz, W.A. and Hatina, J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006, 10(1): 100-125 (Pubitemid 44874294)
82. Croce, C.M. Oncogenes and cancer. N Engl J Med 2008, 358(5): 502-511
83. Walton, T.J., Li, G., Seth, R., McArdle, S.E., Bishop, M.C. and Rees, R.C. DNA demethylation and histone deacetylation inhibition cooperate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell- lines. Prostate 2008, 68(2): 210-222 (Pubitemid 351186233)
84. Morey Kinney, S.R., Smiraglia, D.J., James, S.R., Moser, M.T., Foster, B.A. and Karpf, A.R. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 2008, 6(8): 1365-1374
85. Day, J.K., Bauer, A.M., DesBordes, C. et al. Genistein alters methylation patterns in mice. J Nutr 2002, 132(8 Suppl): 2419S-23S.
86. Fang, M.Z., Chen, D., Sun, Y., Jin, Z., Christman, J.K. and Yang, C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005, 11(19 Pt 1): 7033-7041
87. Hoffmann, M.J., Engers, R., Florl, A.R., Otte, A.P., Muller, M. and Schulz, W.A. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007, 6(9): 1403-1412 (Pubitemid 351590350)
88. Geiman, T.M., Sankpal, U.T., Robertson, A.K., Zhao, Y. and Robertson, K.D. DNMT3B interacts with hSNF2H chromatin remodeling enzyme, HDACs 1 and 2, and components of the histone methylation system. Biochem Biophys Res Commun 2004, 318(2): 544-555 (Pubitemid 38553814)
89. Myant, K. and Stancheva, I. LSH cooperates with DNA methyltransferases to repress transcription. Mol Cell Biol 2008, 28(1): 215-226
90. Xiong, Y., Dowdy, S.C., Podratz, K.C. et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 2005, 65(7): 2684-2689 (Pubitemid 40490068)
91. Esteve, P.O., Chin, H.G., Smallwood, A. et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006, 20(22): 3089-3103 (Pubitemid 44790625)
92. Ruthenburg, A.J., Li, H., Patel, D.J. and Allis, C.D. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007, 8(12): 983-994 (Pubitemid 350174643)
93. Seligson, D.B., Horvath, S., Shi, T. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046): 1262-1266 (Pubitemid 40943093)
94. Hassig, C.A. and Schreiber, S.L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1997, 1(3): 300-308
95. Kikuno, N., Shiina, H., Urakami, S. et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 2008, 123(3): 552-560 (Pubitemid 351898412)
96. Suenaga, M., Soda, H., Oka, M. et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002, 97(5): 621-625 (Pubitemid 34087800)
97. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128(4): 693-705.
98. Basak, S., Pookot, D., Noonan, E.J. and Dahiya, R. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 2008, 7(10): 3195-3202
99. Shapiro, E., Huang, H., Ruoff, R., Lee, P., Tanese, N. and Logan, S.K. The heterochromatin protein 1 family is regulated in prostate development and cancer. J Urol 2008, 179(6): 2435-2439
100. Patra, S.K., Patra, A., Zhao, H., Carroll, P. and Dahiya, R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun 2003, 302(4): 759-766 (Pubitemid 36294038)
101. Yaqinuddin, A., Abbas, F., Naqvi, S.Z., Bashir, M.U., Qazi, R. and Qureshi, S.A. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes. Biosci Rep 2008, 28(6): 319-326
102. Srinivasan, R., Mager, G.M., Ward, R.M., Mayer, J. and Svaren, J. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Cem 2006, 281(22): 15129-15137 (Pubitemid 43855102)
103. Wong, A.K., Shanahan, F., Chen, Y. et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000, 60(21): 6171-6177 (Pubitemid 30839650)
104. Medina, P.P. and Sanchez-Cespedes, M. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics 2008, 3(2): 64-68